1. Clinical & Scientific Overview
Tramadol Hydrochloride (TIP-MED-000109, Reference Code [7.7]) is classified under
Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07) as a Weak Centrally Acting Mu-Opioid Receptor Agonist & Serotonin/Norepinephrine Reuptake Inhibitor (SNRI Analgesic).
Within the Indian regulatory and compendial framework, it is governed under Schedule H1 Prescription Drug (Mandatory Red-Bordered Rx Warning & 3-Year Register under Rule 65 of Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 07 [7.7], p. 82): Contramal (Abbott), Ultram, Domadol; Widely dispensed in FDC with Paracetamol (37.5 mg Tramadol + 325 mg Paracetamol): Ultracet (Janssen), Calpol-T (GSK), Dolokind-Plus, Tramasure-P — Strengths & Dosage Forms: Oral Capsules / Tablets: 50 mg; Sustained-Release (SR/OD) Tablets: 100 mg; FDC Tablets: Tramadol 37.5 mg + Paracetamol 325 mg; Parenteral Injection: 50 mg/mL (1 mL, 2 mL)
Oral Capsules / Tablets: 50 mg; Sustained-Release (SR/OD) Tablets: 100 mg; FDC Tablets: Tramadol 37.5 mg + Paracetamol 325 mg; Parenteral Injection: 50 mg/mL (1 mL, 2 mL)
3. Mechanism of Action & Pharmacodynamics
Weak Centrally Acting Mu-Opioid Receptor Agonist & Serotonin/Norepinephrine Reuptake Inhibitor (SNRI Analgesic) acting on target receptor/enzyme pathways in Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07): clinical efficacy is mediated via Weak Centrally Acting Mu-Opioid Receptor Agonist & Serotonin/Norepinephrine Reuptake Inhibitor (SNRI Analgesic) for Moderate-to-severe acute or chronic pain (postoperative, cancer pain, severe osteoarthritic/radicular pain, fracture pain) when non-opioid analgesics are inadequate or contraindicated (e.g., NSAID-contraindicated CKD patients, at reduced renal dose)..
4. Therapeutic Indications & Evidence-Supported Uses
- Moderate-to-severe acute or chronic pain (postoperative, cancer pain, severe osteoarthritic/radicular pain, fracture pain) when non-opioid analgesics are inadequate or contraindicated (e
- , NSAID-contraindicated CKD patients, at reduced renal dose)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Immediate-Release: 50 mg to 100 mg every 6 to 8 hours as needed (Maximum 400 mg/day in adults <75 years; Maximum 300 mg/day in elderly >75 years). Ultracet FDC (37.5/325 mg): 1 tablet every 6–8 hours SOS (typically 1–3 tablets/day). Dosing strictly depends on renal and hepatic function! Follow physician prescription.
Administration & Meal Timing: With or without food (taking after food or with a biscuit significantly reduces tramadol-induced nausea and dizziness). | Every 6–8 hours SOS, or at bedtime if night pain predominates.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Strictly renal-function dependent! Excreted 90% renally (parent + active M1 metabolite). If CrCl <30 mL/min: extend dosing interval to every 12 hours and do NOT exceed 100 mg–200 mg/day (e.g., max half to one Ultracet tablet twice daily); avoid SR formulations in severe CKD! Hepatic: In cirrhosis, extend interval to every 12 hours (50 mg every 12 h max).
Renal: Strictly renal-function dependent! Excreted 90% renally (parent + active M1 metabolite). If CrCl <30 mL/min: extend dosing interval to every 12 hours and do NOT exceed 100 mg–200 mg/day (e.g., max half to one Ultracet tablet twice daily); avoid SR formulations in severe CKD! Hepatic: In cirrhosis, extend interval to every 12 hours (50 mg every 12 h max).
Renal: Strictly renal-function dependent! Excreted 90% renally (parent + active M1 metabolite). If CrCl <30 mL/min: extend dosing interval to every 12 hours and do NOT exceed 100 mg–200 mg/day (e.g., max half to one Ultracet tablet twice daily); avoid SR formulations in severe CKD! Hepatic: In cirrhosis, extend interval to every 12 hours (50 mg every 12 h max).
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in uncontrolled epilepsy or seizure history (tramadol lowers the seizure threshold!), acute respiratory depression, head injury/raised intracranial pressure, acute intoxication with alcohol/hypnotics, and within 14 days of MAO inhibitors. Requires CYP2D6 bioactivation to active O-desmethyltramadol (M1).
Key Clinical Precautions: Renal: Strictly renal-function dependent! Excreted 90% renally (parent + active M1 metabolite). If CrCl <30 mL/min: extend dosing interval to every 12 hours and do NOT exceed 100 mg–200 mg/day (e.g., max half to one Ultracet tablet twice daily); avoid SR formulations in severe CKD! Hepatic: In cirrhosis, extend interval to every 12 hours (50 mg every 12 h max).
8. Adverse Effects Profile
- Nausea, vomiting, dizziness/vertigo (20–30%, especially upon standing or ambulating!), drowsiness/somnolence, constipation, sweating, dry mouth, pruritus.
- Generalised tonic-clonic seizures (even at high therapeutic doses or when combined with SSRIs/TCAs), Serotonin Syndrome (agitation, clonus, hyperreflexia, fever, diaphoresis), severe hyponatraemia (SIADH—especially in elderly women!), respiratory depression, orthostatic falls and hip fractures, hypoglycaemia (rare idiosyncratic reaction).
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CRITICAL SEROTONIN & SEIZURE INTERACTION: Combining Tramadol with SSRIs (sertraline, escitalopram, fluoxetine), SNRIs (duloxetine, venlafaxine), Tricyclic Antidepressants (amitriptyline), Linezolid, or MAOIs triggers life-threatening Serotonin Syndrome and Seizures! Furthermore, fluoxetine and paroxetine inhibit CYP2D6, blocking conversion of tramadol to its pain-relieving M1 metabolite while increasing parent-drug serotonergic toxicity
- Ondansetron partially antagonises tramadol analgesia (Wait or use domperidone/metoclopramide cautiously for tramadol nausea)
- Benzodiazepines, pregabalin, and alcohol cause dangerous additive CNS/respiratory depression
- Warfarin INR may increase
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Advise taking the first dose while sitting or lying down at home after food, as tramadol frequently causes wave-like dizziness and nausea when walking around. Do not drive or operate machinery. If prescribed Ultracet, count the 325 mg Paracetamol inside toward the daily paracetamol limit. Co-prescribe a gentle osmotic laxative (Lactulose/PEG) if used for >3–5 days.
- Meal & Clock Timing Instruction: With or without food (taking after food or with a biscuit significantly reduces tramadol-induced nausea and dizziness). (Every 6–8 hours SOS, or at bedtime if night pain predominates.)
- Missed Dose Protocol: Used SOS; if scheduled, take as soon as remembered unless near next dose. Never double.
- Geriatric Dispensing Pearl: Beers Criteria Warning: High risk of falls, fractures, delirium, chronic constipation, and SIADH hyponatraemia in elderly CGHS patients. Start with a very low dose (e.g., half tablet of Ultracet [18.75 mg tramadol] after food) and screen out concurrent SSRIs/amitriptyline.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Capsules / Tablets: 50 mg; Sustained-Release (SR/OD) Tablets: 100 mg; FDC Tablets: Tramadol 37.5 mg + Paracetamol 325 mg; Parenteral Injection: 50 mg/mL (1 mL, 2 mL)
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 07 [7.7] (p. 82)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [7.9] Gabapentin — Gabapentinoid; Voltage-Gated Calcium Channel Alpha-2-Delta (α2δ)
- [7.10] Allopurinol — Xanthine Oxidase Inhibitor (Purine Analogue; Metabolised to Activ
- [7.11] Febuxostat — Non-Purine Selective Xanthine Oxidase Inhibitor; Urate-Lowering A
- [7.12] Methotrexate (Low-Dose Weekly Immunomodulator / DMARD Regimen) — Folate Antimetabolite (Dihydrofolate Reductase & AICAR Transformy
